Biomedical Science Letters (대한의생명과학회지)

The Korean Society for Biomedical Laboratory Sciences (대한의생명과학회)
권호 표지
DOI QR코드

DOI QR Code

Effect of Fomes fomentarius Extract in Muscle Atrophy Rat Model

  • Gil-Hyun Lee (Department of Clinical Laboratory Science, Wonkwang Health Science University) ;
  • Kyung-Yae Hyun (Department of Clinical Laboratory Science, DongEui University)
  • Received : 2023.09.25
  • Accepted : 2023.11.03
  • Published : 2023.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

This study was conducted to induce muscle loss using dexametasone and then use the extract to determine its effectiveness in a muscle loss animal model. Animal experimental groups were divided by five groups. Changes in the weight of the animals were measured for a total of 5 weeks. After animal sacrifice, muscle mass was measured, and animal behavior evaluation was conducted using grip strength test and pole test. The expression levels of MAFbx protein was measured using muscle samples. Oral administration of Fomes fomentarius extract was effective in suppressing muscle atropy and increasing muscle, which was confirmed through animal behavior evaluation and muscle-related protein expression.

Keywords

References

  1. Adams V, Linke A, Gielen S, Erbs S, Hambrecht R, Schuler G. Modulation of Murf-1 and MAFbx expression in the myocardium by physical exercise training. European Journal of Preventive Cardiology. 2008. 15: 293-299. https://doi.org/10.1097/HJR.0b013e3282f3ec43
  2. Bodine SC, Baehr LM. Skeletal muscle atrophy and the E3 ubiquitin ligases MuRF1 and MAFbx/atrogin-1. American Journal of Physiology-Endocrinology and Metabolism. 2014. 307: E469-E484. https://doi.org/10.1152/ajpendo.00204.2014
  3. Cao RY, Li J, Dai Q, Li Q, Yang J. Muscle atrophy: present and future. Muscle Atrophy. 2018. 605-624.
  4. Chiriboga CA. Nusinersen for the treatment of spinal muscular atrophy. Expert Review of Neurotherapeutics. 2017. 17: 955-962. https://doi.org/10.1080/14737175.2017.1364159
  5. Cruz-Jentoft AJ, Sayer AA. Sarcopenia. The Lancet. 2019. 393: 2636-2646. https://doi.org/10.1016/S0140-6736(19)31138-9
  6. Dirks AJ, Leeuwenburgh C. The role of apoptosis in age-related skeletal muscle atrophy. Sports Medicine. 2005. 35: 473-483. https://doi.org/10.2165/00007256-200535060-00002
  7. Edstrom E, Altun M, Hagglund M, Ulfhake B. Atrogin-1/MAFbx and MuRF1 are downregulated in aging-related loss of skeletal muscle. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences. 2006. 61: 663-674. https://doi.org/10.1093/gerona/61.7.663
  8. Elkhateeb W, Elnahas MO, Paul W, Daba GM. Fomes fomentarius and Polyporus squamosus models of marvel medicinal mushrooms. Biomed Res Rev. 2020. 3: 1-4.
  9. Gaper J, Gaperova S, Pristas P, Naplavova K. Medicinal value and taxonomy of the tinder polypore, Fomes fomentarius (Agaricomycetes): a review. International Journal of Medicinal Mushrooms. 2016. 18.
  10. Jeyasingham RA, Baird AL, Meldrum A, Dunnett SB. Differential effects of unilateral striatal and nigrostriatal lesions on grip strength, skilled paw reaching and drug-induced rotation in the rat. Brain research Bulletin. 2001. 55: 541-548. https://doi.org/10.1016/S0361-9230(01)00557-3
  11. Jogo M, Shiraishi S, Tamura TA. Identification of MAFbx as a myogenin-engaged F-box protein in SCF ubiquitin ligase. FEBS Letters. 2009. 583: 2715-2719. https://doi.org/10.1016/j.febslet.2009.07.033
  12. Lee GH, Lee JS, Kang DY, Hyun KY. Anti-nociceptive actions of Fomes fomentarius extract on the formalin test in the rat. JoKULL Journal. 2016. Vol 66, No 9.
  13. Malkawi AK, Alzoubi KH, Jacob M, Matic G, Ali A, Al Faraj A, Abdel Rahman AM. Metabolomics based profiling of dexamethasone side effects in rats. Frontiers in Pharmacology. 2018. 9: 46.
  14. Morley JE, Abbatecola AM, Argiles JM, Baracos V, Bauer J, Bhasin S. Sarcopenia with limited mobility: an international consensus. Journal of the American Medical Directors Association. 2011. 12: 403-409. https://doi.org/10.1016/j.jamda.2011.04.014
  15. Park YM, Kim IT, Park HJ, Choi JW, Park KY, Lee JD, Lee KT. Anti-inflammatory and anti-nociceptive effects of the methanol extract of Fomes fomentarius. Biological and Pharmaceutical Bulletin. 2004. 27: 1588-1593. https://doi.org/10.1248/bpb.27.1588
  16. Patel S, Goyal A. Recent developments in mushrooms as anticancer therapeutics: a review. Biotech. 2012. 2: 1-15. https://doi.org/10.1007/s13205-011-0036-2
  17. Rom O, Reznick AZ. The role of E3 ubiquitin-ligases MuRF-1 and MAFbx in loss of skeletal muscle mass. Free Radical Biology and Medicine. 2016. 98: 218-230. https://doi.org/10.1016/j.freeradbiomed.2015.12.031
  18. Schorling DC, Pechmann A, Kirschner J. Advances in treatment of spinal muscular atrophy-new phenotypes, new challenges, new implications for care. Journal of Neuromuscular Diseases. 2020. 7: 1-13. https://doi.org/10.3233/JND-190424
  19. Troncoso R, Paredes F, Parra V, Gatica D, Vasquez-Trincado C, Quiroga C, Lavandero S. Dexamethasone-induced autophagy mediates muscle atrophy through mitochondrial clearance. Cell Cycle. 2014. 13: 2281-2295. https://doi.org/10.4161/cc.29272
  20. Vinciguerra M, Musaro A, Rosenthal N. Regulation of muscle atrophy in aging and disease.Protein Metabolism and Homeostasis in Aging. 2010. 211-233.
  21. Westerblad H, Bruton JD, Katz A. Skeletal muscle: energy metabolism, fiber types, fatigue and adaptability. Experimental Cell Research. 2010. 316: 3093-3099. https://doi.org/10.1016/j.yexcr.2010.05.019
  22. Zungu M, Schisler JC, Essop MF, McCudden C, Patterson C, Willis MS. Regulation of AMPK by the ubiquitin proteasome system. The American Journal of Pathology. 2011. 178: 4-11. https://doi.org/10.1016/j.ajpath.2010.11.030